Sabra Health Care REIT (SBRA) fundamentals: P/E, valuation, undervalued?
Sabra Health Care REIT · Real Estate · ref. ETF XLRE · price $20.7
In short — Sabra Health Care REIT trades at 79.6× earnings (P/E), 26.7× forward, with a net margin of 7.6 % and revenue growth of +25 %. Read: Fairly valued (P/E 27 in line with ~25% growth (PEG 1.1)).
Is Sabra Health Care REIT stock cheap or undervalued? A good time to buy? Here are its fundamentals — P/E, PEG, margin and income statement — to judge its valuation.
📈 1-year price
$20.7+7.2% over range
Aug 28, 25low $17.23 · high $22.39Aug 27, 26
📏 Click 2 points (left → right) to measure the change · click again to clear.
SellBuy
Hold
30% recommend buying · 10 analysts
Valuation : Fairly valued — P/E 27 in line with ~25% growth (PEG 1.1)
Valuation
79.6
P/E (price/earnings)
26.7
Forward P/E
—
PEG
1.9
Price/book (P/B)
$5.3B
Market cap
0.26
EPS
Profitability & growth
7.6 %
Net margin
+25 %
Revenue growth
—
Earnings growth
$2.6B
Total debt
Sabra Health Care REIT income statement
| Fiscal year | Revenue | Net income | Margin |
|---|---|---|---|
| 2022 | $625M | $-78M | -12.4 % |
| 2023 | $648M | $14M | 2.1 % |
| 2024 | $703M | $127M | 18.0 % |
| 2025 | $775M | $156M | 20.1 % |
⚠️ Indicative financial data (Yahoo Finance), not investment advice. Amounts in $.
Frequently asked questions
What is Sabra Health Care REIT's P/E and is the stock undervalued? What's a good P/E?
Sabra Health Care REIT's P/E is 79.6 (forward 26.7). Below ~15 = fairly cheap, above ~30 = expensive. Our valuation verdict: "Fairly valued".
Is Sabra Health Care REIT profitable?
Sabra Health Care REIT has a net margin of 7.6 % (EPS 0.26). The company is profitable.
Is SBRA stock expensive?
Our read: "Fairly valued" — P/E 27 in line with ~25% growth (PEG 1.1). Cross-check with growth and sector.
💬 A question about Sabra Health Care REIT? The JPI assistant answers using our backtest data.
Keep exploring Sabra Health Care REIT